When the grade-3 BC samples were classified into molecular subtypes, the proportion of cases with a high ColXVIII score were the biggest in the HER2 (~89%) and in the basal/TNBC (~86%) groups (Figure 2C and Supplemental Table 3A), indicating that prominent ColXVIII expression was associated with the aggressiveness of the BC. The gene discussed is ERBB2; the disease is breast cancer.